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Treatment of Hepatitis C (HCV) is emerging as
the most controversial subject in correctional
health care. Much of the controversy around
HCV testing and treatment in corrections is
related to delayed recognition of the important
role incarcerated individuals play in the trans-
mission of hepatitis in the communities after
they are released. State and Federal public
health officials have been slow to recognize the
potential benefits of screening, educating, and
where possible, vaccinating incarcerated per-
sons to prevent morbidity and mortality associ-
ated with viral hepatitis.
The Centers for Disease Control (CDC) took
action this Spring, convening a meeting on
Hepatitis in correctional settings that was
attended by more than 100 federal and
state correctional healthcare professionals.1
Representatives of correctional
organizations (ACA, NCCHC) and
representatives from federal agen-
cies such as the OSHA and NIOSH
also attended the meeting. CDC
speakers discussed the need to
expand HBV and HCV interven-
tions, including screening, educa-
tion, vaccination, and treatment of chronic
hepatitis in correctional settings. Guidelines for
HCV and HBV management incorporating
some of the discussion points will be issued by
the CDC as a supplement to the MMWR in the
Fall. While sources of funding for increased
hepatitis interventions in corrections were not
specifically addressed at this meeting, promot-
ing correctional settings as outposts for public
health activities may ultimately lead to
increased financial support from federal and
state sources for correctional treatment initia-
tives.
In keeping with this new national focus on
hepatitis in corrections, HEPP News is dedicat-
ing two of the next three issues to updates on
hepatitis management. This issue addresses
HCV in corrections and summarizes discus-
sions at the CDC meeting. The second article,
scheduled for June 2001, will take up the topic
of Hepatitis B and Hepatitis A immunizations in
correctional settings.
HCV Epidemiology
HCV and HBV outstrip HIV in terms of sheer
numbers of inmates living with these two infec-
tions (Figure 1, Table 1). In the US, there are an
estimated 4.5 million individuals living with
chronic HCV infection, and 1.2 million with
chronic HBV infection. 79% of current injection
drug users have HCV infection.3
G Inmates At Risk
Non hispanic blacks and hispanics
have higher rates of HCV and HBV
infection and chronic disease than
whites; most cases of HCV and
HBV infections are found among
persons who are male, members of minority
populations, and 30 to 49 years of age.6
These race and class-related risk factors for
hepatitis infection probably contribute to the
current concentration of HCV and HBV-infected
persons in prisons and jails. 
According to a recent analysis by Ted Hammett
for the NIJ and the NCCHC’s report to
Congress7, between 1.0 to 1.25 million individ-
uals harboring chronic HCV infection were
released from prisons and jails in the U.S. in
1996, or approximately 30% (29 to 32%) of the
total population living with HCV in the U.S. The
prevalence of HCV infection among U.S. pris-
oners is at least 10 fold higher than the estimat-
ed 2% prevalence in the general population.8
This ratio is based on estimates that 17% of
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state inmates are infected with HCV.9
HCV infection rates have ranged from 28%
(Texas) to 67% of a higher risk subpopula-
tion of inmates (those with abnormal liver
function tests or who are known to have
HIV infection) in New Jersey. Reflecting
their higher rate of participation in HIV and
HCV risk behaviors, incarcerated women
exhibit about a third higher HCV co-infec-
tion rate than incarcerated men.10(Figure 2).
Rationale for Screening
Approximately 50% of persons with
hepatitis are unaware of their hepatitis
infection.22 Testing for infection informs
the patient and physician about the poten-
tial for and possible existence of liver
damage. It should serve as an important
prompt for a discussion about risky behav-
iors and transmission to others.23 The
CDC lists correctional institutions, HIV coun-
seling and testing sites, and drug and STD
treatment programs as sites where hepatitis
screening and interventions should take
place. (See Table 2 for recommendations.)
G Reducing the cost of screening
If the cost of screening an incarcerated
population for HCV appears to be prohibi-
tive, targeted screening can reduce the
cost of screening and still identify most
HCV at-risk individuals. For example, in a
Wisconsin study of HCV screening in a
local prison, 60.5% of HCV infections were
identified by screening those who had his-
tory of IDU. By including any individuals
who also had an ALT > 51, the facility iden-
tified 79.6% of HCV infections. Adding a
history of liver disease to the criteria for
testing allowed the identification of 83.6%
of HCV-infected individuals. When individu-
als who were HBV+ were also screened,
the correctional facility identified 90.8% of
the HCV infections. The cost of testing was
reduced by two thirds (compared to mass
screening) using their criteria, and was very
effective.25
Treatment of HCV
For those who are to be treated, initial
treatment of chronic HCV with
ribavirin/interferon alfa is now the standard
of care in community settings. Many cor-
rectional facilities are in the process of
developing protocols for deciding which
patients will be eligible for treatment (see
the Correctional Medical Services triage
form HEPPigram Part I on page 6 for an
example). 
G Treatment selection criteria
Criteria for HCV treatment may vary slight-
ly from one correctional system to another.
In general, eligible patients (1) have evi-
dence of persistent HCV infection and
inflammation based on liver function test
abnormalities and detectable virus in the
blood stream; (2) have enough time left in
their sentence to allow for completion of
treatment (from six to 12 months) (3) are
committed to a life free from substance and
alcohol abuse; and (4) are educated about
potential HCV treatment side effects and
willing to adhere to an arduous course of
treatment. (See HEPPigram on page 6 for
guidance on selecting patients for HCV
treatment.)
Standard therapy is to provide daily treat-
ment with Ribavirin (usually five to six pills
divided into two doses) and thrice-weekly
alfa-interferon injections. (See HCV 101 on
page 8 for dosing and side effects of treat-
ment regimens). Pegylated interferon, a
new form of interferon that permits once-
weekly dosing, is available as PEG-Intron
(peginterferon alpha-2b), and Pegasys is
expected to be approved by the FDA later
this Spring. Monotherapy is currently only
used if the patient cannot take Ribavirin
due to toxicities or side-effects. 
G Duration of treatment
Current recommendations on the duration
of treatment are as follows:
Duration of Combination therapy depends
on viral genotype:
HCV genotype 2 or 3: 
A 24-week (six month) course of combina-
tion therapy yields results equivalent to
those of a 48-week (12 month) course. 
HCV genotype 1: 
A 48-week (12 month) course yields a sig-
nificantly better sustained response rate
than does six months of treatment.
Duration of Interferon monotherapy: 48-
weeks, regardless of genotype.
G Expected Response: Combination
Therapy versus Monotherapy
Combination therapy consistently yields
higher rates of sustained response than
monotherapy. (A sustained response
implies that HCV RNA remains unde-
tectable for six months or more after thera-
py stops.) With combination therapy, 40%
of treatment-naïve patients respond.
Patients with genotype-1 have sustained
response rates of 25 to 30% (slightly better
response rates are seen with lower base-
line HCV viral loads). Non-genotype-1
patients achieve response rates of 60 to
65%.26,27 Other factors that increase the
likelihood of a response to therapy include
age <45, female gender, and mild (rather
than advanced) chronic inflammation on
liver biopsy. Histologic improvement occurs
in 86% of patients who achieve a sustained
response (SVR) and 39% of patients who
relapse after initial response to combination
therapy.28 Just as with HIV therapy, adher-
ence is critical to obtain maximal response.
Adherence to therapy has also been shown
to increase the likelihood of a response to
therapy. The SVR increases from 40% to
48% when patients receive at least 80% of
both their interferon dose and their ribavirin
dose for > 80% of the recommended dura-
tion.29
G Pegylated delivery: Another Step
Forward in Hepatitis C Therapy
Pegylated forms of interferon allow once
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Table 1. Hepatitis and HIV Disease Prevalence 
Chronic Infections
New Infections per year
Deaths per year
Number of infected inmates released
__% of US population
4.5 million
35,000
8,000
1.3-1.4 million
29-32%
1.2 million
120,000
5,000
155,000**
12.4-15.5%
0.8 million
40,000
18,000
98,000-145,000
13-19%
HCV HBV
Hepatitis and HIV prevalence in US populations^
Hepatitis and HIV prevalence among inmates released from prisons and jails*
HIV
Continued on page 4
^CDC, Harold Margolis, Hepatitis Branch.4
* Burden of disease among releasees in 1996, CDC, NIJ, Abt survey.5
**Hammet et al. noted an extreme lack of HBV data on correctional populations.  These numbers are
rough period prevalence estimates based on studies done in California (1994) and New York (1987-
1997) correctional systems.
Figure 2. Prevalence of HCV Infection in Selected States
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This figure shows the prevalence of HCV in certain state correctional populations.  Percentages are
shown by gender were data were available.  These prevalence studies are not necessarily comparable
across states because different methods were used to compile the data.  HCV prevalence in reporting
states is the following; California: 40% of men and 54% of women;11 Connecticut: 32% of women;12
Colorado: 30%;13 Maryland: 38%;14 Massachusetts: 20.7% (Hamden County);15 Texas: 28% of
the men and 37% of women;16 Virginia: 30-40%;17 Washington: 30-40%;18 Wisconsin: 21% of
women, 12.4% of men, 13.2% overall;19 Pennsylvania: 13%;20 Arizona: 31.3%.21
HCV... (continued from page 1)
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Dear Colleagues,
As our experience with highly active antiretroviral therapy and long-term survival expands, we now manage co-
morbid diseases that never had time to manifest in the past, such as Hepatitis C (HCV). HCV infection con-
tributes to the deaths of an estimated 8,000 - 10,000   Americans each year. This toll is expected to triple by the
year 2010 and exceed the number of annual deaths due to AIDS, according to the CDC. 
Hepatitis C infection shares many of the epidemiologic risk factors associated with HIV.  Indeed, coinfection
rates in the HIV+ population average 30-35%, but can be as high as 100% in specific settings. Thus, testing for
the co-related virus is a must in order to provide early intervention and evaluation, as well as begin risk reduc-
tion counseling and training.   
Treatment options for both viruses are also unclear. Some HIV antiretrovirals appear to have a greater risk for
hepatotoxicity than others, independently of HCV infection.  The treatment balance lies in the ability to effectively
evaluate the HCV infection with not only viral load, genotype and imaging, but also with liver biopsy as chemi-
cal hepatitis often does not correlate with the degree of liver injury present. 
As with many other chronic medical conditions, morbidity and/or mortality attributable to HCV may not manifest
itself until well after the end of incarceration. Consequently, correctional systems, when faced with the dilemma
of prioritizing treatment for HCV, may choose to spend the funds otherwise, or not at all. Much of the contro-
versy is related to the cost of a therapy that is difficult to administer and, in many cases, ineffective.  Additionally,
the therapy in most cases is being given to IDUs who are in forced institutional abstinence, have not and will not
have drug treatment, and will therefore probably be promptly reinfected upon release.
Despite these concerns, some state medical directors have lead the way and adopted clear protocols for the
screening and treatment of HCV in their facilities. These visionaries are mindful that a year 2001 dollar spent on
treatment may reduce the cost (to society) of caring for patients who may require liver transplants in 20 to 30
years. Furthermore, combination therapy of HCV is leading to higher rates of cure (up to 88% in selected
patients), therefore, the overall cost effectiveness of HCV interventions in corrections is improving. Obviously,
more data are needed to more concretely guide our treatment programs.  Until then, we can only continue to do
the best with what information we have.
After reviewing this issue, readers should be able to describe the rationale for HCV testing and treatment, review
the interactions between HCV and HIV, describe the risk of HCV infection for inmates and correctional workers,
and provide preliminary information on new formulations of therapy. Thank you for your continued support of
HEPP News!
Sincerely,
Michael T. Wong, MD, 
Assistant Professor of Medicine, Division of Infectious Diseases, Beth Israel Deaconess Medical Center
Letter from the Editor
3
Subscribe to HEPP News
Fax to 617.770.3339 for any of the following: (please print clearly or type)
____  Yes, I would like to add/update/correct (circle one) my contact information for my complimentary subscription of HEPP News fax/email newsletter.
____  Yes, I would like to sign up the following colleague to receive a complimentary subscription of HEPP News fax/email newsletter.
____  Yes, I would like to have the following back issues emailed to me (please include volume/issue/date).
____  Yes, I would like my HEPP News to be delivered in the future as an attached PDF file in an email (rather than have a fax).
NAME: 
FACILITY: (Optional) # of HIV-Infected Inmates:
CHECK ONE:
ADDRESS:
CITY: STATE: ZIP:
FAX: PHONE: EMAIL:
SIGNATURE: DATE: 
Senior Advisors
Theodore M. Hammett, Ph.D.
Abt Associates
Ned E. Heltzer, R.Ph., M.S.
Ralf Jürgens
Canadian AIDS Law Legal Network
David P. Paar, M.D.
University of Texas Medical Branch
Joseph Paris, Ph.D., M.D.
CCHP Georgia Dept. of Corrections 
David Thomas, J.D., M.D.
Florida Dept. of Corrections
Lester Wright, M.D.
New York State Dept. of Corrections
Associate Editors
Dean Rieger, M.D.
Indiana Dept. of Corrections
Josiah Rich, M.D.
Brown University School of Medicine,
The Miriam Hospital
Stephen Tabet, M.D., M.P.H.
Univ. of Washington Division of Infectious
Disease Seattle HIVNET
David A. Wohl, M.D. 
University of North Carolina
Managers
Dennis Thomas
Brown University AIDS Program
Michelle Gaseau
The Corrections Connection
Layout
Kimberly Backlund-Lewis
The Corrections Connection
Distribution
Screened Images Multimedia
Managing Editor 
Elizabeth Stubblefield
HIV Education Prison Project
The editorial board and contributors to HEPP
News include national and regional correctional 
professionals, selected on the basis of their 
experience with HIV care in the correctional 
setting and their familiarity with current HIV 
treatment. We encourage submissions, feed-
back, and correspondence from our readership.
Physician Physician Assistant Nurse Practitioner Nurse/Nurse Administrator
Pharmacist          Medical Director/Administrator HIV Case Worker/Counselor        Other
April 2001     Volume 4, Issue 4 visit HEPP News online at www.hivcorrections.org
4weekly dosing, improving adherence to ther-
apy and possibly improving response to ther-
apy. A phase III study demonstrated that the
combination of peginterferon alfa-2b (1.5
mcg/kg once weekly) plus ribavirin was sig-
nificantly more effective than the combina-
tion of standard interferon alfa-2b plus rib-
avirin, particularly in patients with genotype 1
virus.30, 31 SVR rates in this study were
dependent on the actual dose received.
Overall, patients who received >10.6
mg/kg/daily of ribavirin plus 1.5 mcg/kg/QW
of peginterferon alfa-2b achieved a SVR of
61%. The SVR in genotype 1 patients was
48% and the SVR in non-genotype 1 patients
was 88%.32
This study also demonstrated that these
response rates could be further increased if
patients were able to maintain adherence.
Regardless of genotype, patients who
received the recommended combination reg-
imen and received >80% of their treatment
had a higher sustained response than those
who received < 80% of their treatment (72%
vs. 46%).  Genotype 1 patients who received
the optimal weight-based dose of peginter-
feron alfa-2b plus ribavirin and adhered to at
least 80% of their regimen  achieved a SVR
of 63%.  Similar patients with genotype 2 or
3 infection achieved a SVR of 94%.33, 34
G Liver Biopsy
The need for confirming the extent of dam-
age to the liver by HCV and chronic HBV
infection is another area of debate, since
obtaining liver biopsies can be both costly
and logistically complicated in correctional
settings. Liver function tests can be normal in
patients with rather advanced cirrhotic fea-
tures. Likewise, liver function tests may be
consistently elevated in Hepatitis C patients
with normal histology. Some state correction-
al systems do not routinely perform liver
biopsies prior to initiating treatment, because
of cost and logistical difficulties.  Other states
(e.g. FL) feel biopsies are the only real way
to measure disease progression over time
and therefore have made arrangement to do
them on site at very reduced costs ($200 per
biopsy). Depending on the cost of obtaining
a liver biopsy, electing to treat all incarcerat-
ed individuals who meet the criteria for treat-
ment may be more cost-effective, for society
as a whole, than management by biopsy.35
G Lowest cost intervention: Education
The lowest cost intervention for the preven-
tion of hepatitis infection is education. Given
the risk of acquiring HCV (not to mention
HIV), all bloodborne pathogen screening
events should lead to careful discussion of
the risks of acquiring HBV and HCV infection
(for those patients who have negative hepati-
tis serologies). The risk of transmitting
hepatitis should also be made very clear
(see Resources on page 9 for educational
materials). 
The impact of continued drug use should
also be made very clear to patients, espe-
cially those who are not yet HCV infected.
Young injection drug users (IDUs) acquire
HCV infection at rates four times higher than
the rate of acquisition of HIV; after 5 years of
injection drug use, 90% of IDUs are HCV
infected. For those inmates already  infected
with HCV, education should be provided on
the impact of alcohol abuse on HCV pro-
gression (four fold increase in risk of pro-
gression, risk of liver damage directly corre-
lated with alcohol intake) and the risk of
transmission to uninfected sexual partners.
Inmates who have HCV infection should, at
the very least, be educated about options for
treatment even if they are not eligible for
treatment while incarcerated (see Resources
on page 9 for expanded access programs).
G Additional considerations
Another lower (but not no-cost) intervention
is vaccination. For HCV infected patients,
vaccination against HBV and HAV is routine-
ly recommended, as these relatively inex-
pensive vaccines may reduce the risk of ful-
minant liver failure and the need for liver
transplantation for HCV-infected patients. A
new schedule of HBV vaccination (three
shots at 0, 1, and 4 months) has received
approval. The first shot provides up to 50%
protection, and the series does have efficacy
even if prolonged over several years, so the
new CDC guidelines are expected to encour-
age HBV vaccination even in jail settings.
Should patients be ineligible for treatment
due to lack of time to complete the treatment,
they should be provided with the hotline
numbers to access free HCV treatments, if
eligible, after release. Contact the compa-
nies for more information on their expanded
access programs (see Newsflashes page 9).
Cost of HCV treatment
With the high prevalence of HCV infection
among incarcerated individuals, there is a
concern that treatment could overwhelm
some systems’ healthcare budgets. Medical
decision analyst J. Wong calculated that six
months of combination therapy resulted in
net savings in the range of $400 to $3500
over the lifetime of each HCV infected
patient.36 Dr. Wong’s analysis ranked combi-
nation therapy for HCV in the same range of
cost effectiveness as stool guiac testing,
pneumococcal vaccination, coronary bypass
surgery, and mammography. It must be
noted however that the cost savings that
may accrue from treatment of prisoners are
primarily to society as a whole. While treat-
ment of incarcerated individuals for hepatitis
and HIV is the right thing to do and can
tremendously benefit the public health, it is
not realistic to expect correctional systems to
shoulder this financial burden without assis-
tance.  
G Management
Since the incidence of side effects to HCV
combination therapy can be relatively high,
and it can be difficult for incarcerated
patients to quickly access their clinician to
report side effects, it is important to:
spend time preparing the patient for the
potential treatment-related side effects,
consider following the patients in a dedi-
cated hepatitis clinic, 
HCV... (continued from page 2)
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Persons who should be tested routinely for hepatitis include:
G Persons residing in correctional facilities 
G IDU, including those who injected once or a few times and do not currently 
consider themselves to be drug users. 
G Persons with selected medical conditions, including:•
- Persons who received clotting factor concentrates produced before 1987
- Persons ever on chronic hemodialysis;
- Persons with persistently abnormal ALT levels. 
G Persons who received blood transfusions, blood components, or organ 
transplantation before July 1992 
G Persons diagnosed with HIV infection  and sexual partners of persons 
diagnosed with HIV infection 
G Healthcare  and correctional workers after needle sticks, sharps, or mucosal 
exposures to HCV-positive blood. 
Table 2. HCV / HBV Screening
Source: Modified from MMWR, 199824
Table also applies to HCV/HIV patients
G Baseline
-HIV viral load, CD4, CBC, LFTs,  
Chem panel, HCV load, genotype
-Screen for co-morbid disease
-Depression screen (consider 
anti-depressant prophylaxis)
G Week 2
-CBC
-If anemic; erythropoeitin
G 4 week intervals
-CBC, LFTs, Chem panel
-Evaluate mood, adverse effects
G 12 week intervals
-HCV VL, HIV VL, CD4
-Evaluate for drug-drug interactions
-Screen for IFN-associated thyroid  
dysfunction (TSH)
G Check HCV VL week 12 and 24 
-Week 12: 
HCV RNA > 1 log reduction 
-Week 24: 
HCV RNA undetectable
-If genotype 1, continue TX for 48 
weeks. If non-genotype 1, stop 
therapy after 24 weeks.
VL (viral load); CBC (complete blood
count); LFTs (liver function tests); 
Chem (chemistry panel); TSH (thyroid
stimulating hormone).
Table 3. Monitoring HCV Treatment
Continued on page 5
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use a nurse or other staff person to regu-
larly check in with patients who are receiv-
ing HCV treatment so that side effects can
be rapidly addressed.
One suggestion for reducing the cost of man-
aging chronically HCV infected individuals in
corrections is to make use of existing "chron-
ic disease" clinic infrastructure and expertise
existing on site - since HIV and HCV are fel-
low travelers, and correctional medical units
might insist that the ID (HIV) expert acquire
expertise in HCV and HBV management.
Some clinics have set up flow sheets to
reduce repetitive, unnecessary testing.
Without a good support system, a high per-
centage of patients will fail to complete ther-
apy.  Because of the high cost of treatment,
time spent preparing patients and supporting
them while on treatment is likely to be cost
effective. 
HIV and HCV co-infection
Cellular immune response (T helper cells or
CD4 T cells and Cytotoxic T lymphocytes or
CD8 T cells) is involved in mounting an
immune defense against the virus. Clearly,
HCV infected individuals who also have
advanced HIV infection may be less able to
respond to HCV infection due to their com-
promised cellular immune response. 
Analyses of the effect of HCV and HIV co-
infection on progression of either disease are
often confounded by concurrent risk factors
for progression. However, available data
seems to indicate that HIV infection
accelerates HCV liver disease. Persons who
are co-infected (HIV / HCV) appear to have a
12 to 300 fold higher risk of developing hepa-
tocellular carcinoma than non-carriers.37
Furthermore, antiretroviral agents can con-
tribute to liver inflammation, and this may be
more frequent in those who have underlying
chronic hepatitis due to HCV or HBV.
Ritonavir appears to be one of the ART med-
ications that is most commonly associated
with liver inflammation in HCV/HIV co-
infected patients.38
The impact of HCV infection on HIV infection
is less clear. In some studies, HCV infection
does not appear to have an effect on the
progression of HIV.39 Other studies have
reported an association between more rapid
progression to AIDS or death in HIV-infected
patients; particularly among those who were
co-infected with HCV genotypes 1a and
1b.40, 41 However, a report by Sulkowski at
CROI contraindicated these findings, sug-
gesting that risk of progression was more
linked to lack of access to medical care (for
HIV) in his cohort of African American
patients who had HIV and HCV co-infection
(CROI abstract 34).
Response to HCV therapy in individuals who
also have HIV infection appears to be equiv-
alent to that of non-HIV infected individu-
als.42 A recent study in the Journal of the
American Medical Association by Sulkowski
et al indicates that 88% of co-infected
patients tolerate concurrent HCV treatment
and HAART.43 Following successful HCV
treatment, co-infected patients are not more
likely to relapse after HCV treatment than are
patients who do not have concurrent HIV
infection.
Currently, when exclusionary criteria are not
present (see Table 2), treatment of hepatitis
C is recommended for patients when CD4
and viral load values reflect good response
to antiretroviral treatment. Although some
controversy remains in regard to the defini-
tion of a good response to HAART, a stable
CD4 T cell count greater than 200 with a sta-
ble viral load less than 400 is generally
accepted.44
Conclusion
In summary, the high prevalence of hepatitis
infections among incarcerated individuals
and the availability of treatments with less
than 100% efficacy forces difficult decision
making in correctional health facilities.
Combination IFN/ribavirin therapy is now the
standard of care. National guidelines and
standards for selecting patients who are to
be treated, while providing access to care for
HCV infected individuals regardless of incar-
ceration status, are forthcoming from the
CDC. The cost of HCV treatment is expected
to be a major barrier to wide implementation
of the guidelines in prisons and jails.
Correctional physicians eagerly anticipate
further guidance from state and federal
health officials on supplemental sources of
funding for HCV treatment initiatives in cor-
rectional settings.
HCV... (continued from page 4)
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6HEPPigram Part I: Management and Treatment of Chronic HCV
This information has been adapted and reproduced with permission from CMS, Inc., St. Louis, MO, the developer of the work.  It is
solely for the educational use of the provider and is not meant to substitute for the individual medical judgment of the provider.  Expert 
consultation is advised.
STEP 1: Medical Evaluation
Medical Evaluation:
G History and Physical
G Patient education
- Liver damage prevention
- Disease transmission
G Lab testing, liver function (ALT)
Patient meets criteria for therapy (Step 1).
Is ALT elevated 1.5x upper normal**?
YES
Complete Hepatitis C Medical
evaluation utilizing evaluation
form (see HEPPigram Part II).
Does patient meet additional cri-
teria for treatment?
NO
Stop: Does not meet criteria for
HCV Therapy
STEP 2: Treatment and Management
Educate patient about vaccines, treatment side effects, 
and obtain consent for treatment.
Initiate therapy under direction of a specialist.  Obtain genotype 
(will determine length of treatment. See HCV 101)
Evaluate for side effects (see HCV 101)
6 months after treatment, check ALT and HCV-RNA. 
Does HCV RNA remain positive?
YES
Mild side effects: Administer drug
in the evening. Reassure patient.
Antipyretics prior to q dose.
Severe side effects:
May require dosage adjustment
or discontinuation of therapy.
NO
Continue therapy.  Monitor ALT.
If ALT increases during therapy,
treatment should be 
discontinued.
YES
Consider treatment failure and
discontinue therapy.
NO
If genotype 1a or 1b, continue
therapy for 6 more months.
If non-genotype 1, discontinue.
Examine patient monthly and
monitor ALT.
YES
Recheck ALT and HCV RNA 6
months after end of therapy to
evaluate effectiveness of therapy.
NO
Consider treatment failure and
discontinue therapy.
YES
Refer for liver biopsy.
NORMAL RESULTS:
Do not treat but continue to monitor. 
ABNORMAL RESULTS:
Initiate treatment by proceeding to step 2.
MILD HISTOLOGIC FINDINGS:
If patient does not wish to be treated, 
continue to monitor and biopsy periodically 
(See Table 3, main article).
NO
Stop.  Continue to monitor 
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Check ALT and HCV RNA at end of therapy. 
Is ALT normal and HCV RNA negative at 12 months?
** Different institutions may use different criteria for eligibility
 Hepatitis A and Hepatitis B vaccination are recommended if immunity is not already established. 
HEPPigram Part II: One Approach to Hepatitis C Medical Evaluation
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This information has been adapted and reproduced with permission from CMS, Inc., St Louis, MO, the developer of the work. It is
solely for the educational use of the provider and is not meant to substitute for the individual medical judgment of the provider. Expert
consultation is advised.
RATIONALE
Screen for HCV Infection if risk factors (blood prod-
ucts before 1990 or IDU in patient with increased
ALT), no confirmatory test needed.
Confirm chronic hepatitis elevated ALT (three tests,
>1 month apart over previous 12 months, average
>1.5 x upper normal). 
No evidence of treatment benefit if under age 18 or
over 60 years of age
Treatment for HCV is lengthy with significant side
effects.
Ribavirin causes birth defects.
Heavy ethanol use or injecting drug use will elimi-
nate HCV treatment benefit.
HCV progresses slowly and therapy is problematic;
treatment must be completed while incarcerated.  If
not able to complete treatment courses during incar-
ceration, treatment should be deferred until release.
Hepatitis C treatment is arduous, which makes
patient adherence and compliance mandatory.
Interferon worsens hyperthyroidism.
Interferon worsens autoimmune disease: SLE,
rheumatoid arthritis, MCTD, Scleroderma, etc.
Interferon causes solid organ transplant rejection.
Interferon reduces platelets, especially in the 
first 4-6 weeks.
Interferon in combination with ribavirin will decrease
Hbg 2.5-3.1 in 4-6 weeks.
Interferon in combination with ribavirin will reduce
WBC’s.
Interferon therapy in combination with ribavirin may
exacerbate cerebrovascular disease.
Interferon therapy in combination with ribavirin may
exacerbate heart failure.
Interferon therapy in combination with ribavirin can
cause renal failure.
There is no evidence of therapy benefits in patients
with decompensated cirrhosis. There is little evi-
dence of benefit and very low sustained response in
patients with compensated cirrhosis.
Interferon may cause or exacerbate major 
depression.
Co-infection of HIV and HCV requires that HIV be
controlled.
Co-infection with HBV and HCV may require higher
doses of interferon.
OBJECTIVE
Positive HCV-EIA?
#1 ALT _____ date _____
#2 ALT _____ date _____
#3 ALT _____ date _____
Average >1.5x upper normal? 
Age____  Age >18 and <60?
Has patient received education regarding length of thera-
py, possible side effects, and expected outcomes and
consents to therapy?
Willing to use contraception if released during treatment
and for 6 mos post treatment? 
Woman HCG negative?
Free of substance abuse misconduct guilty 
findings for previous 12 months?
Consents to random drug testing?
Maximum release date:_____
Maximum release date in >18 months?
History of non-compliance to medical therapy 
and/or follow-up? 
TSH: __________  Results indicate hyperthyroidism?
Convincing evidence of autoimmune disease?
ANA: __________
History of solid organ transplant?
Platelet count: _____  Platelets <100,000?
Hbg: __________  Hbg within normal limits?
WBC: __________
WBC’s within normal limits (>3,000cells/cubic ml)?
Does patient have a history of cerebrovascular disease?
Does patient have history of coronary artery disease or
heart failure?
Is serum creatinine stable at <2.0?
Variceal bleed past/present?
Encephalopathy past/present?
Evidence of ascities?
Albumin: ________ Albumin <3.0?
PT: ________ PT >14?
Alpha fetoprotein:________ AFP>50?
Total bilirubin/conj bilirubin:________
Is patient jaundiced?
History of major depression or suicide ideation?
History of major psychiatric illness?
HIV Ab positive?
HIV Ab:________? Date: _____
If HIV positive: CD4: _______ Viral load: _______
HbsAg: __________
Yes       No
Yes       No
Yes       No
Yes       No
Yes       No
Yes       No
Yes       No
Yes       No
Yes       No
Yes       No
Yes       No
Yes       No
Yes       No
Yes       No
Yes       No
Yes       No
Yes       No
Yes       No
Yes       No
Yes       No
Yes       No
Yes       No
Yes       No
Yes       No
Yes       No
Yes       No
Yes       No
Yes       No
Yes       No
Yes       No
FINDINGS
8TREATMENT
(Trade Name)
Ribavirin: oral
antiviral agent**+
Interferon alfa-
2a, interferon
alfa-2b, consen-
sus interferon
Interferon alfa-2a
(Roferon A)
Interferon alfa-2b
(Intron A)
Peginterferon
alfa 2b (PEG-
Intron. Pegasys
by Roche is
expected later
this year)
Interferon
alfacon-1
(Infergen)
COST^
(Manufacturer)
Ribavirin: 
$1.25 per 200mg capsule
1000mg: $43.75/week
1200mg: $52.50/week  
See below for interferons.
Rebetron** 1200 
(Schering-Plough): 
$391.00 per week
Rebetron** 1000: 
$354.00 per week 
Rebetron 600:  
$290.00 per week
$36.72 per 3MU (Roche)
$40.00 per 3 MU 
(Schering-Plough)
100mcg/ml : $240.00
160mcg/ml : $253.00
240mcg/ml: $265.00
300mcg.ml : $279.00
(Schering-Plough)
$38.76 per 9ug(Amgen)
DOSE
Ribavirin:
200mg capsules
(1000mg/day
divided BID or
<75kg;
1,200mg/day
divided BID for
>75kg)
Interferons: 3 
million units (MU)
/injection;
consensus 
interferon 
9 mcg/injection.
3 MU/injection
3 MU/injection
Monotherapy:
1mcg/kg per
weekCombination
therapy:
1.5mcg/kg per
week
consensus 
interferon 
9 mcg/injection.
FREQUENCY
2x day
3x week
sub-cutaneous
3x weekly
sub-cutaneous
3x weekly
sub-cutaneous
1x weekly
3x weekly
MAJOR SIDE EFFECTS^^
Primary toxicity: hemolytic anemia
(reductions of hemoglobin levels
occurred within the first 1-2 weeks
of therapy). 
Rebetron: cardiac and pulmonary
events associated with anemia
occur in approximately 10% of
patients. Psychiatric events in
treatment naive: insomnia (39%),
depression (34%), 
irritability (27%).
Most patients experience 
flu-like symptoms: headache,
dizziness,nausea/vomiting, 
diarrhea, depression, 
irritability, insomnia.
Some patients experience:
Neutropenia, Thrombocytopenia,
Depression, Anemia  
H
C
V
 
1
0
1 Hepatitis C Treatment
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Combination Therapy
Monotherapy
*Reserve for patients who have contraindications to Ribavirin.
**Currently, Ribavirin is only available from Schering-Plough packaged with Interferon alfa-2b as Rebetron or compounded by Fisher’s
Pharmacy (3904 Perrysville Ave., Pittsburgh, PA 15214; 888-347-3416).  Rebetron contains Interferon 3 MU plus 1200mg, 1000mg, or
600mg Ribavirin, and is packaged in 2 week supplies.
^ The pricing shown should be considered a maximum price.  Substantially discounted pricing may be available based upon the type of
pharmacy purchasing medications (ex. institutional, retail, government operated).  In addition, quantity or market share rebates from the
manufacturer may be available. Prices are subject to change at any time.
^^ Most of the reported adverse reactions are considered mild to moderate and are manageable.
DETAILS ARE IN TEXT
Adapted from Chronic Hepatitis C: Current Disease Management. NIH Publication No. 99-4230, May 1999. www.niddk.nih.gov.
CME is Now Available Online at www.hivcorrections.org:
HEPP readers are now able to take HEPP News’ continuing medical education (CME) tests online at
http://www.HIVcorrections.org. Any internet browser will enable you to take the HEPP News CME tests every month.
Your test results will be registered with the Brown Medical School Office for Continuing Medical Education.  When you
pass the test, you can either download your CME certificate from the website or request Brown to send the certificate in
the mail. Try it out this week!
National Hepatitis 
Awareness Month
May 2001
For details, see Hepatitis
Foundation International,
http://www.hepfi.org.
Infectious Disease Society of
America (IDSA): 39th Annual
Meeting
October 25-28, 2001
San Francisco, California
Abstract deadline: May 22, 2001
Late-breaker abstract deadline:
August 20, 2001
Discounted registration deadline:
July 30, 2001
Write: 99 Canal Center Plaza, 
Suite 210 Alexandria, VA 22314
Fax: 703.299.0204
Visit: www.idsociety.org
The 5th Annual HIV Update:
Contemporary Issues in
Management
May 31-June 2, 2001
Cambridge, Massachusetts
Email: hms-cme@hms.harvard.edu
Visit: http://134.174.17.108/
conted-bin/hmscme
Call: 617.432.1525
Fax: 617.432.1562
Fee: $530/full fee; $340/residents
and fellows in training; $340/non-
physician fee. Continuing medical
education credits are available.
Management of HIV/ AIDS in the
Correctional Setting: A Live
Satellite Videoconference Series
"Management of the HIV/
Hepatitis C Co-infected Patient"
June 5, 2001  
12:30-3:30 p.m. EST
CME Credits Available through
Albany Medical Center.
Call: 518.262.4674
Email: rosentjh@mail.amc.edu 
Visit: www.amc.edu/patient/HIV/
hivconf.htm 
Overview of Adult HIV Care for
Health Professionals
June 4-6, 2001 
Atlanta, Georgia
Email: pyeargi@emory.edu
Visit: http://www.seatec.emory.edu
Call: 404.727.2938
Fax: 404.727.4562
Fee: $150, includes book, 
syllabus material, and optional 
clinical rotation. 
Continuing education 
credits available.
Save the 
Dates
9
Resources
HEPP News includes new focus on Hepatitis
Almost one third of our nation’s Hepatitis C
cases occur among recently released prison
and jail inmates.  For this reason, HEPP News
has expanded its focus to include topics on
Hepatitis C.  Our new name is the HIV and
Hepatitis Education Prison Project (our
acronym will remain the same: HEPP).
We are happy to announce new  members of
our advisory board, Dr. Dean Rieger, Medical
Director of the Indiana Department of
Corrections, and Dr. Josiah Rich, Associate
Professor of Medicine and Community Health,
Brown University School of Medicine, and
Attending Physician at The Miriam Hospital.  
We would also like to acknowledge our financial
supporters for the year 2001, and thank those
that funded us last year.  Renewing their annu-
al support, HEPP News is grateful for the unre-
stricted educational grants from Abbott
Laboratories, Agouron Pharmaceuticals,
Boehringer-Ingelheim/Roxane Laboratories,
DuPont Pharmaceuticals, Merck  & Co. , and
Roche Pharmaceuticals. Schering-Plough
Corporations has joined our supporters. In
addition, OrthoBiotech has contributed baseline
support.  
Hepatitis C Rising in Arizona State Prisons
Hepatitis C (HCV) is on the rise in Arizona state
prisons.  While an estimated 1.4 million HCV-
infected prisoners spend time in the nation’s jail
system each year, Arizona estimates that
approximately 6,000 of its 26,800 inmates are
infected with the disease.  Prison doctors esti-
mate that between 700 and 1,000 are eligible
for treatment; however, who will pay for that
treatment is causing controversy. Treating HCV
would cost the Arizona Department of
Corrections between $8,700 and $16,200 per
eligible inmate. (Madrid D. Denver Post.
2/17/01 P. A28. www.denverpost.com)
Hidden Behind Bars: Hepatitis C
Hepatitis C in prisons has picked up attention
from the Reuters News Service, a backbone for
the general press. An April 5 Reuters report
included commentary from HEPP News editor
Anne De Groot, Ted Hammett of Abt Associates
and HEPP News Advisor, and various national
HCV and HIV prison experts. The article calls
Hepatitis C "a silent killer" and reported that
medical experts say HCV is not only rampant
among the almost two million inmates of U.S.
prisons and jails, but authorities are not making
enough effort to combat it.  Reuters interviewed
Hammett about a study he conducted for the
Texas prison system which concluded it would
cost $40 million a year to diagnose and treat
prisoners for hepatitis C in that state. The com-
plete story is available at www.reuters.com or
by calling the Washington newsroom 202-898-
8300.
New Releases: Pegylated Interferon
Schering-Plough has received FDA approval
for use of Peginterferon alfa-2b (PEG-Intron) in
monotherapy, and is expecting approval for use
with Ribavirin later this year. Peginterferon alfa-
2b  is a longer-acting form of interferon alfa-2b
(Intron A) that is a once-weekly therapy
designed to optimize the balance between
antiviral activity and elimination half-life. Roche
Laboratories is also expecting approval for their
peginterferon alfa-2b, known as Pegasys.  Both
companies have reimbursement plans for their
Hepatitis C medications. For Schering-Plough,
call Commitment to Care at 1-800-521-7151
(9:00am-8pm). For Roches reimbursement
plan, call the Hepline Reimbursement Hotline
800-443-6676, option 3 (8:30am-5:00pm).  For
more information, call Schering-Plough at (908)
298-4000 or visit http://www.pegintron.com,
and call Roche at 800-526-6367 or visit:
http://www.rocheusa.com.
News Flashes
The Price of Punishment
Hepatitis C in prisons. A WBUR interview with
A. De Groot and J. Noonan.
http://www.wbur.org/prison/hepatitis.shtml
Combination Therapy
Projects in Knowledge (slide sets and CME
materials supported by an unrestricted grant
from Schering Oncology/Biotech)
http://www.projectsinknowledge.com/
HepC-DDW/home.htm 
Hepatitis C Awareness News is a free edu-
cational newsletter. Staff and inmates can sub-
scribe by writing to: Hepatitis C Awareness
Project, PO Box 41803, Eugene, OR 97404.
HEPATITIS WEBSITES:
CDC hepatitis home page
http://www.cdc.gov/ncidod/diseases/hepatitis/i
ndex.htm
NIH’s National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK)
http://www.niddk.nih.gov
HIV and Hepatitis C Co-Infection: ATIS
http://www.hivatis.org/hepatitisC.html
American Liver Foundation
http://www.liverfoundation.org
Canadian Hepatitis information website
http://www.hepnet.com/index.html
HCV Advocate: News and information web-
site on HCV and HIV/HCV coinfection
http://www.hcvadvocate.org
HCV Prison News: A new website dedicated
to hepatitis C and HIV/HCV coinfection in 
prisons
http://hcvprisonnews.org
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit for Bloodborne Pathogens Universal
Precautions and the AMA Physician’s Recognition Award. To be eligible for CME credit, answer the questions below by circling the 
letter next to the correct answer to each of the questions. A minimum of 70% of the questions must be answered correctly. 
This activity is eligible for CME credit through August 31, 2001. The estimated time for completion of this activity is 
one hour and there is no fee for participation.
1. Which of the following indicate the correct schedule(s) for HBV
vaccine?
a) 0, 6, 12 months
b) 0, 1, 4 months
c) 0, 2, 6 months
d) 0, 3, 6 months
e) a and b
f) b and c
2. A patient infected with HCV genotype 2 who is eligible for treat-
ment can expect which duration for treatment?
a) 16-week (4 month) course of combination therapy
b) 24-week (6 month) course of combination therapy
c) 48-week (12 month) course of combination therapy
d) 6-12 months of therapy; depending on weather LFTs 
show response to treatment.
3. At what point should you consider treatment failure and discon-
tinue therapy?
a) After initiating therapy if patient presents severe side effects.
b) At 6 months, if HCV RNA remains positive.
c) At 12 months, if HCV RNA remains positive.
d) All of the above
e) None of the above; treatment success cannot be measured 
until after therapy is complete.
4. Which of the following statements are false?
a) Persons being treated for HCV should use contraception 
during treatment and for 6 months post treatment because 
ribavirin can cause birth defects.
b) Interferon in combination with ribavirin can exacerbate 
cerebrovascular disease and heart failure, and can cause 
renal failure.
c) Treatment for HCV is lengthy with significant side effects, 
therefore should not be initiated in the correctional setting.
d) Monotherapy should only be used for patients who have 
contraindications for ribavirin.
e) a and b.
f) b and c.
5. Indicate which of the following statements are true about HCV
and HIV coinfection:
a) Persons who are co-infected (HIV/HCV) appear to have a 12 
to 300 fold higher risk of developing hepatocellular carcinoma 
than non-carriers.
b) HIV infection accelerates HCV liver disease.
c) A majority of patients can tolerate concurrent treatment for 
HCV and HIV.
d) a and b.
e) All of the Above.
f) None of the above.
6. Approximately ___ of US HCV infections occur in people
released from prisons or jails:
a) 2%
b) 11%
c) 24%
d) 30%
e) 50%
BROWN MEDICAL SCHOOL   OFFICE OF CONTINUING MEDICAL EDUCATION   BOX G-A2    PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical 
education activities for physicians.  
The use of the Brown Medical School name implies review of the educational format and material only.  The opinions, recommendations 
and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the 
Brown Medical School.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or 
register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP News Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1     
HEPPigram 5  4  3  2  1   5  4  3  2  1  
HCV 101 5  4  3  2  1   5  4  3  2  1
Save the
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPP News be made more useful to you?
5. Do you have specific comments on this issue?
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